Nykode Therapeutics ASA (NYKD) - Total Liabilities

Latest as of June 2026: Nkr5.73 Million NOK ≈ $602.86K USD

Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has total liabilities worth Nkr5.73 Million NOK (≈ $602.86K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Nykode Therapeutics ASA's assets to evaluate the company's liquid asset resilience ratio.

Nykode Therapeutics ASA - Total Liabilities Trend (2016–2025)

This chart illustrates how Nykode Therapeutics ASA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Nykode Therapeutics ASA (NYKD) total assets.

Nykode Therapeutics ASA Competitors by Total Liabilities

The table below lists competitors of Nykode Therapeutics ASA ranked by their total liabilities.

Company	Country	Total Liabilities
The Ruby Mills Limited NSE:RUBYMILLS	India	Rs-6.74 Billion
Dynacor Gold Mines Inc. TO:DNG	Canada	CA$46.47 Million
India Pesticides Limited NSE:IPL	India	Rs3.26 Billion
BIDV Insurance Corp VN:BIC	Vietnam	₫6.53 Trillion
Shutterstock NYSE:SSTK	USA	$728.62 Million
Black Spade Acquisition II Co Unit NASDAQ:BSIIU	USA	$6.81 Million
Companhia Energética de Brasília - CEB SA:CEBR3	Brazil	R$197.14 Million
Vestel Elektronik Sanayi ve Ticaret AS IS:VESTL	Turkey	TL155.67 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Nykode Therapeutics ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Nykode Therapeutics ASA net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	11.52	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.07	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.07	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nykode Therapeutics ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nykode Therapeutics ASA (2016–2025)

The table below shows the annual total liabilities of Nykode Therapeutics ASA from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	Nkr8.42 Million ≈ $885.82K	-51.25%
2024-12-31	Nkr17.27 Million ≈ $1.82 Million	-53.24%
2023-12-31	Nkr36.93 Million ≈ $3.89 Million	-42.71%
2022-12-31	Nkr64.46 Million ≈ $6.78 Million	-9.85%
2021-12-31	Nkr71.50 Million ≈ $7.52 Million	+39.71%
2020-12-31	Nkr51.18 Million ≈ $5.39 Million	+1.30%
2019-12-31	Nkr50.52 Million ≈ $5.32 Million	+280.83%
2018-12-31	Nkr13.27 Million ≈ $1.40 Million	+21.29%
2017-12-31	Nkr10.94 Million ≈ $1.15 Million	+528.02%
2016-12-31	Nkr1.74 Million ≈ $183.26K	--

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$166.04 Million

Nkr1.58 Billion NOK

Market Cap Rank

#17364 Global

#147 in Norway

Share Price

Nkr4.03

Change (1 day)

+1.51%

52-Week Range

Nkr1.58 - Nkr4.99

All Time High

Nkr91.25